Coherus Oncology, Inc.CHRSNASDAQ
Loading
EBITDA as a percentage of revenue
Percentile
P38
Within normal range
vs 5Y Ago
-12.2x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | -416.41% | -1924.2% |
| 2024 | 22.83% | +130.3% |
| 2023 | -75.39% | +37.7% |
| 2022 | -121.10% | -51.7% |
| 2021 | -79.83% | -334.7% |
| 2020 | 34.01% | +9.1% |
| 2019 | 31.18% | +100.2% |
| 2018 | -13137.28% | +9.3% |
| 2017 | -14481.75% | -23468.4% |
| 2016 | -61.45% | - |